# NVO — slm-full-cpu

## Metadata

ticker: NVO
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: c98503203e0a3a3377ff0be4048f87ae4a40bcdb7be0c6f3a8c0d85ceec5c5ee
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 5
llm_endpoints: slm-cpu
llm_by_site: {"section:financial_health": {"calls": 1, "completion_tokens": 134, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 46.678, "latency_s_total": 46.678, "parse_failure": 0, "prompt_tokens": 456, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 135, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 34.905, "latency_s_total": 34.905, "parse_failure": 0, "prompt_tokens": 450, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 152, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 37.042, "latency_s_total": 37.042, "parse_failure": 0, "prompt_tokens": 446, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 109, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 27.081, "latency_s_total": 27.081, "parse_failure": 0, "prompt_tokens": 454, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 838, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 90.093, "latency_s_total": 90.093, "parse_failure": 0, "prompt_tokens": 1496, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NVO",
  "company_name": "Novo Nordisk A/S",
  "current_price": 37.525,
  "currency": "USD",
  "market_cap": 165648678912.0,
  "pe_ratio": 9.174817,
  "forward_pe": 11.280802,
  "week_52_high": 64.16,
  "week_52_low": 35.12,
  "financial_currency": "DKK",
  "revenue": 329430990848.0,
  "net_income": 116442996736.0,
  "profit_margin_pct": 35.35,
  "dividend_yield": 4.79,
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General"
}

NEWS ARTICLES:
[
  {
    "title": "Novo Nordisk Slims Down Name to Novo",
    "source": "The Wall Street Journal",
    "published_at": "2026-09-14T12:41:00Z",
    "description": "The Wegovy maker is betting that a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly."
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "message": "No 10-K found"
  },
  "10-Q": {
    "message": "No 10-Q found"
  }
}

RAG — SEC HIGHLIGHTS:
(not available)

RAG — RISK FACTORS:
(not available)

## Pre-written sections (judge input)

### Financial Health

Novo Nordisk trades at $37.53 with a market capitalization of $165.65 billion, reflecting a compelling valuation with a P/E ratio of 9.17. The company demonstrates exceptional profitability, generating DKK 329.43 billion in revenue and DKK 116.44 billion in net income, resulting in a robust profit margin of 35.35%. This strong financial performance is supported by a healthy dividend yield of 4.79%, underscoring the firm's ability to generate substantial cash flow despite recent operational rebranding efforts.

### Recent Developments
Novo Nordisk has officially rebranded to "Novo," a strategic move designed to enhance consumer resonance and strengthen its competitive position against rival Eli Lilly in the weight-loss drug market. This branding shift underscores the company's aggressive expansion beyond its traditional diabetes focus into the broader obesity treatment sector. With the company reporting DKK 329.4 billion in revenue and DKK 116.4 billion in net income, the rebranding aims to capitalize on its strong financial performance and high profit margins. Investors should monitor how this simplified identity impacts brand loyalty and market share growth in the highly contested GLP-1 arena.

### SEC Filing Highlights
No recent 10-K or 10-Q filings were available for review. Consequently, the analysis relies on reported financial metrics of DKK 329.43 billion in revenue and DKK 116.44 billion in net income. The company maintains a robust profit margin of 35.35% and offers a dividend yield of 4.79%. Strategic initiatives include rebranding to "Novo" to enhance consumer resonance against competitors like Eli Lilly.

### Risk Factors

*   **Brand Rebranding Execution Risk:** The strategic shift to shorten the corporate name to "Novo" carries execution risk, as the company bets that this change will successfully enhance consumer resonance and competitive positioning against rivals like Eli Lilly.
*   **Regulatory and Patent Exposure:** As a leading manufacturer of GLP-1 agonists (e.g., Wegovy), the company faces ongoing risks related to patent litigation, regulatory approval delays, and potential pricing pressures or reimbursement restrictions in key markets.
*   **Currency and Macroeconomic Volatility:** With financial reporting in DKK while trading in USD, Novo Nordisk is exposed to foreign exchange fluctuations that can significantly impact reported revenue, net income, and investor returns.

## Audited (Exec Summary + Outlook)

### Executive Summary
Novo Nordisk is a dominant force in the diabetes and obesity treatment sectors, leveraging a robust profit margin of 35.35% and generating DKK 329.43 billion in revenue to maintain its competitive edge against rivals like Eli Lilly. The stock is currently notable for its compelling valuation, evidenced by a P/E ratio of 9.17, and a healthy dividend yield of 4.79%, which underscores the firm's substantial cash flow generation capabilities. The single most important near-term variable is the successful execution of the strategic rebranding to "Novo," which will determine whether the company can effectively enhance consumer resonance and secure market share in the highly contested GLP-1 arena.

### Outlook
The directional outlook for Novo Nordisk is cautiously constructive, driven by its dominant position in the high-growth obesity treatment market and exceptional profitability metrics. Key variables to monitor include the execution of the "Novo" rebranding strategy, the trajectory of GLP-1 demand, and the company's ability to navigate regulatory and patent landscapes. The thesis would be strengthened by clear evidence of sustained market share gains and successful consumer adoption of the new brand identity, while it would be weakened by significant pricing pressures, reimbursement restrictions, or adverse foreign exchange movements that erode the reported DKK-denominated earnings.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "robust profit margin of 35.35%"
LABEL: SUPPORTED
REASON: The raw source data explicitly states `"profit_margin_pct": 35.35`, and the pre-written sections repeat this figure identically.

---

CLAIM: "DKK 329.43 billion in revenue"
LABEL: SUPPORTED
REASON: The raw source data shows `"revenue": 329430990848.0` DKK, which equals approximately DKK 329.43 billion, matching the claim exactly.

---

CLAIM: "P/E ratio of 9.17"
LABEL: SUPPORTED
REASON: The raw source data states `"pe_ratio": 9.174817`; rounded to two decimal places this is 9.17, matching the claim.

---

CLAIM: "dividend yield of 4.79%"
LABEL: SUPPORTED
REASON: The raw source data explicitly states `"dividend_yield": 4.79`, matching the claim exactly.

---

CLAIM: "strategic rebranding to 'Novo'"
LABEL: SUPPORTED
REASON: The news article titled "Novo Nordisk Slims Down Name to Novo" (WSJ, 2026-09-14) explicitly confirms the rebranding to "Novo."

---

**OUTLOOK**

---

CLAIM: "exceptional profitability metrics"
LABEL: SUPPORTED
REASON: This is a qualitative characterization directly supported by the 35.35% profit margin present in the source data; no specific number is asserted beyond what is already audited above.

---

CLAIM: "reported DKK-denominated earnings"
LABEL: SUPPORTED
REASON: The raw source data confirms `"financial_currency": "DKK"` and provides DKK-denominated net income of DKK 116.44 billion, supporting the characterization of DKK-denominated earnings.

---

**ADDITIONAL CHECKS — figures present in source data but not claimed (no omission issues to flag for audit purposes).**

No additional quantitative claims (e.g., specific price targets, forward P/E of 11.28, 52-week high of $64.16, 52-week low of $35.12, market cap of $165.65 billion, net income of DKK 116.44 billion, current price of $37.53) appear in the Executive Summary or Outlook sections, so they require no audit entry.

---

**SUMMARY TABLE**

| Claim | Label |
|---|---|
| Profit margin of 35.35% | SUPPORTED |
| DKK 329.43 billion in revenue | SUPPORTED |
| P/E ratio of 9.17 | SUPPORTED |
| Dividend yield of 4.79% | SUPPORTED |
| Strategic rebranding to "Novo" | SUPPORTED |
| Exceptional profitability metrics (qualitative) | SUPPORTED |
| DKK-denominated earnings | SUPPORTED |

**All auditable quantitative and forward-looking claims in the Executive Summary and Outlook are SUPPORTED by the source data.** No unsupported or inference-only claims were identified.
